Evaluation of health-related quality-of-life and dyspnea scales in patients with idiopathic pulmonary fibrosis. Correlation with pulmonary function tests

Tzanakis, Νikolaos; Samiou, Maria; Lambiri, Irini; Αντωνίου, Κατερίνα; Siafakas, Nikolaos M.; Bouros, Demosthenes

doi:10.1016/j.ejim.2004.09.013

Cited by 77 publications

(66 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although this questionnaire is not specific for interstitial lung diseases [23], it has recently been demonstrated that the SGRQ is a sensitive tool for assessing health-related quality of life in IPF patients [31]. Interestingly, lung volumes (FVC and TLC) and duration of disease correlated with SGRQ score [31].…”

Section: Discussionmentioning

confidence: 99%

Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis

Αντωνίου¹,

Nicholson²,

Dimadi³

et al. 2006

Eur Respir J

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia is a deadly disease with no effective treatment. The purpose of this randomised prospective multicentric study was to characterise the clinical effects of interferon gamma (IFN-c) 1b administered subcutaneously thrice weekly versus colchicine for 2 yrs. This study had no pre-specified end-points.Fifty consecutive IPF patients were randomised. Patients with mild-to-moderate IPF were eligible for the study if they had histologically proven IPF, or, in the absence of surgical biopsy, fulfilled the European Respiratory Society/American Thoracic Society criteria.In the intent-to-treat population, five out of 32 (15.6%) IFN-c-1b patients and seven out of 18 (38.8%) colchicine patients died after a median follow-up period of 25 months Patients treated with IFN-c 1b showed a better outcome after 2 yrs of therapy, and fewer symptoms, as assessed using the St George's Respiratory Questionnaire, after 12 months of therapy. Also, the IFN-c-1b group exhibited a higher forced vital capacity (percentage of the predicted value) after 24 months of treatment. No significant differences were detected in resting arterial oxygen tension, total lung capacity (% pred), transfer factor of the lung for carbon monoxide (% pred) and high-resolution computed tomographic scoring between the two treatment groups.These data suggest that long-term treatment with interferon gamma 1b may improve survival and outcome in patients with mild-to-moderate idiopathic pulmonary fibrosis. Further studies are needed to verify these results.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis

Αντωνίου¹,

Nicholson²,

Dimadi³

et al. 2006

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…Six studies 55,68,72,73,125,126 were based on five RCTs of interventions where HRQoL was an outcome measure, one was a CCT, 61 and four studies were cohort 'before-and-after' studies that tested HRQoL at baseline and then again after an intervention; 110,113,114,116 one of these also had a control group of patients with COPD. 114 Five studies 111,119,[122][123][124] were single-cohort studies with no intervention, three 112,115,118 were single-cohort studies that collected HRQoL data at two different time points (one also had an additional control group 112 ), two studies 109,120 were cohort studies with matched controls, one was a cohort study with subgroup data 127 and one 117 was a combination of a focus group and survey. Seven of the 16 studies using the SF-36 did not report the overall physical or mental health summary scores, [109][110][111]113,114,124,125 one study reported only the overall summary scores (at baseline), 68 one study reported only an overall score encompassing both physical health and mental health component scores, 116 and one study did not present any useful data, reporting data as deviation values from national reference values.…”

Section: Systematic Review Of Health-related Quality Of Life Studiesmentioning

confidence: 99%

“…Two other multicentre studies were US-based only. 68,72 The remaining studies were single-centre studies from countries such as Japan (six studies 73,[112][113][114][115]122 ), Brazil (three studies 109,111,124 ), Poland (three studies 61,112,127 ), Turkey (one study 110 ), Canada (one study 123 ), the Netherlands (one study China (one study 118 ), Greece (two studies 116,120 ) and the USA (one study 55 ). Generalisability of these populations to those seen in current UK practice may, therefore, be limited.…”

Section: Systematic Review Of Health-related Quality Of Life Studiesmentioning

confidence: 99%

“…Nine studies 61,[109][110][111][112][113][114][115][116] assessed HRQoL using the SF-36, seven used the SGRQ, 55,73,[117][118][119][120][121][122] five studies used both the SF-36 and SGRQ [123][124][125][126][127] and two studies used the SF-36, the SGRQ and the EQ-5D 68,72 (Table 65). Two studies used the EQ-5D.…”

Section: Systematic Review Of Health-related Quality Of Life Studiesmentioning

confidence: 99%

“…55,68,72,73,[117][118][119][120][121][122][123][124][125][126][127] The SGRQ is a disease-specific measure which aims to assess the impact of obstructive airways disease on overall health, daily life and perceived well-being. 135 It comprises 50 items within two parts, which cover three components of symptoms, activity and impact.…”

Section: Systematic Review Of Health-related Quality Of Life Studiesmentioning

confidence: 99%

See 2 more Smart Citations

The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation

Loveman

Copley

Colquitt

et al. 2015

Health Technology Assessment

View full text Add to dashboard Cite

BackgroundIdiopathic pulmonary fibrosis (IPF) is a life-limiting lung disease that generally affects people over 60 years old. The main symptoms are shortness of breath and cough, and as the disease progresses there is a considerable impact on day-to-day life. Few treatments are currently available.ObjectivesTo conduct a systematic review of clinical effectiveness and an analysis of cost-effectiveness of treatments for IPF based on an economic model informed by systematic reviews of cost-effectiveness and quality of life.Data sourcesEleven electronic bibliographic databases, including MEDLINE, EMBASE, Web of Science, and The Cochrane Library and the Centre for Reviews and Dissemination databases, were searched from database inception to July 2013. Reference lists of relevant publications were also checked and experts consulted.MethodsTwo reviewers independently screened references for the systematic reviews, extracted and checked data from the included studies and appraised their risk of bias. An advisory group was consulted about the choice of interventions until consensus was reached about eligibility. A narrative review with meta-analysis was undertaken, and a network meta-analysis (NMA) was performed. A decision-analytic Markov model was developed to estimate cost-effectiveness of pharmacological treatments for IPF. Parameter values were obtained from NMA and systematic reviews. Univariate and probabilistic sensitivity analyses were undertaken. The model perspective is NHS and Personal Social Services, and discount rate is 3.5% for costs and health benefits.ResultsFourteen studies were included in the review of clinical effectiveness, of which one evaluated azathioprine, threeN-acetylcysteine (NAC) (alone or in combination), four pirfenidone, one BIBF 1120, one sildenafil, one thalidomide, two pulmonary rehabilitation, and one a disease management programme. Study quality was generally good, with a low risk of bias. The current evidence suggests that some treatments appear to be clinically effective. The model base-case results show increased survival for five pharmacological treatments, compared with best supportive care, at increased cost. General recommendations cannot be made of their cost-effectiveness owing to limitations in the evidence base.LimitationsFew direct comparisons of treatments were identified. An indirect comparison through a NMA was performed; however, caution is recommended in the interpretation of these results. In relation to the economic model, there is an assumption that pharmacological treatments have a constant effect on the relative rate of per cent predicted forced vital capacity decline.ConclusionsFew interventions have any statistically significant effect on IPF and a lack of studies on palliative care approaches was identified. Research is required into the effects of symptom control interventions, in particular pulmonary rehabilitation and thalidomide. Other research priorities include a well-conducted randomised controlled trial on inhaled NAC therapy and an updated evidence synthesis once the results of ongoing studies are reported.Study registrationThis study is registered as PROSPERO CRD42012002116.FundingThe National Institute for Health Research Health Technology Assessment programme.

show abstract

Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study

Jastrzębski,

Kostorz‐Nosal,

Galle

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

Background and AimsAntifibrotic therapies reduce lung function decline in patients with idiopathic pulmonary fibrosis (IPF). This single‐arm, open‐label, nonrandomized study aimed to determine the influence of antifibrotic treatment on patients' reported symptoms and expectations of the therapy.MethodsFifty‐two patients with confirmed IPF at a mean age of 65 ± 8.63 years (73% male) completed the following surveys at baseline and after 12 months of Pirfenidone treatment: Short Form Healthy Survey (SF‐36), St. George's Respiratory Questionnaire (SGRQ), Baseline Dyspnea Index (BDI), Fatigue Assessment Scale (FAS), Leicester Cough Questionnaire (LCQ), and Patient's Needs and Expectations Authors' Survey.ResultsThe most important patients' needs were access to novel therapy, fast and easy access to health centers specializing in IPF treatment, and the improvement of the general condition or the maintenance of its level. These needs did not change with time, except for the significantly more important right of deciding on disease management after 12 months of treatment (p = 0.014). The quality of life per SF‐36, after 1 year of Pirfenidone treatment, significantly improved in the physical cumulative score (p = 0.004) and mental cumulative score (p = 0.003). Significant deteriorations were observed in bodily pain and vitality. For the remaining questionnaires (SGRQ, BDI, FAS, and LCQ), no significant changes in the course of the study were noticed. Around one in 10 patients subjected to Pirfenidone therapy had achieved general symptom improvement in all areas; that is, quality of life improvement as well as cough and dyspnea reduction.ConclusionsOne year of antifibrotic treatment resulted in a general improvement in the quality of life per the SF‐36 questionnaire. Patients' expectations of disease management did not change; also, access to novel therapies and easy access to health centers specializing in IPF management remained their top needs.

show abstract

Evaluation of health-related quality-of-life and dyspnea scales in patients with idiopathic pulmonary fibrosis. Correlation with pulmonary function tests

Cited by 77 publications

References 34 publications

Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis

Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis

The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation

Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study

Contact Info

Product

Resources

About